CoChat
Sign Up
Cited by 81

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Aggregate Clearance of α-Synuclein in Saccharomyces cerevisiae Depends More on Autophagosome and Vacuole Function Than on the Proteasome

Petroi, Doris, Popova, Blagovesta, Taheri-Talesh, Naimeh, Irniger, Stefan, Shahpasandzadeh, Hedieh, Zweckstetter, Markus, Outeiro, Tiago F., Braus, Gerhard H.·2012·Journal of Biological Chemistry
DOI 10.1074/jbc.m112.361865
Open this paper in CoChat — free account

Abstract

Parkinson disease is the second most common neurodegenerative disease. The molecular hallmark is the accumulation of proteinaceous inclusions termed Lewy bodies containing misfolded and aggregated α-synuclein. The molecular mechanism of clearance of α-synuclein aggregates was addressed using the bakers' yeast Saccharomyces cerevisiae as the model. Overexpression of wild type α-synuclein or the genetic variant A53T integrated into one genomic locus resulted in a gene copy-dependent manner in cytoplasmic proteinaceous inclusions reminiscent of the pathogenesis of the disease. In contrast, overexpression of the genetic variant A30P resulted only in transient aggregation, whereas the designer mutant A30P/A36P/A76P neither caused aggregation nor impaired yeast growth. The α-synuclein accumulation can be cleared after promoter shut-off by a combination of autophagy and vacuolar protein degradation. Whereas the proteasomal inhibitor MG-132 did not significantly inhibit aggregate clearance, treatment with phenylmethylsulfonyl fluoride, an inhibitor of vacuolar proteases, resulted in significant reduction in clearance. Consistently, a cim3-1 yeast mutant restricted in the 19 S proteasome regulatory subunit was unaffected in clearance, whereas an Δatg1 yeast mutant deficient in autophagy showed a delayed aggregate clearance response. A cim3-1Δatg1 double mutant was still able to clear aggregates, suggesting additional cellular mechanisms for α-synuclein clearance. Our data provide insi…

Overview

Integrity signals

Registry

Crossref · 10.1074/jbc.m112.361865

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 69

  1. Galvin, 2001, Synucleinopathies. clinical and pathological implications, Arch. Neurol., 58, 186, 10.1001/archneur.58.2.186 · DOI
  2. Forno, 1996, Electron microscopy of Lewy bodies in the amygdala-parahippocampal region. Comparison with inclusion bodies in the MPTP-treated squirrel monkey, Adv. Neurol., 69, 217
  3. Spillantini, 1997, α-Synuclein in Lewy bodies, Nature, 388, 839, 10.1038/42166 · DOI · Paper page
  4. Maroteaux, 1988, Synuclein. A neuron-specific protein localized to the nucleus and presynaptic nerve terminal, J. Neurosci., 8, 2804, 10.1523/JNEUROSCI.08-08-02804.1988 · DOI
  5. Singleton, 2003, α-Synuclein locus triplication causes Parkinson disease, Science, 302, 841, 10.1126/science.1090278 · DOI · Paper page
  6. Hardy, 2006, Genetics of Parkinson disease and parkinsonism, Ann. Neurol., 60, 389, 10.1002/ana.21022 · DOI
  7. Polymeropoulos, 1997, Mutation in the α-synuclein gene identified in families with Parkinson disease, Science, 276, 2045, 10.1126/science.276.5321.2045 · DOI · Paper page
  8. Krüger, 1998, A30P mutation in the gene encoding α-synuclein in Parkinson disease, Nat. Genet., 18, 106, 10.1038/ng0298-106 · DOI · Paper page
  9. Giasson, 1999, Mutant and wild type human α-synucleins assemble into elongated filaments with distinct morphologies in vitro, J. Biol. Chem., 274, 7619, 10.1074/jbc.274.12.7619 · DOI
  10. Lashuel, 2002, α-Synuclein, especially the Parkinson disease-associated mutants, forms pore-like annular and tubular protofibrils, J. Mol. Biol., 322, 1089, 10.1016/S0022-2836(02)00735-0 · DOI
  11. Conway, 2001, Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct, Science, 294, 1346, 10.1126/science.1063522 · DOI · Paper page
  12. Volles, 2002, Vesicle permeabilization by protofibrillar α-synuclein is sensitive to Parkinson disease-linked mutations and occurs by a pore-like mechanism, Biochemistry, 41, 4595, 10.1021/bi0121353 · DOI
  13. Karpinar, 2009, Pre-fibrillar α-synuclein variants with impaired β-structure increase neurotoxicity in Parkinson disease models, EMBO J., 28, 3256, 10.1038/emboj.2009.257 · DOI · Paper page
  14. Taschenberger, 2012, Aggregation of α-synuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons, Acta Neuropathol., 123, 671, 10.1007/s00401-011-0926-8 · DOI
  15. Gajula Balija, 2011, Pre-fibrillar α-synuclein mutants cause Parkinson disease-like non-motor symptoms in Drosophila, PLoS One, 6, e24701, 10.1371/journal.pone.0024701 · DOI
  16. Winner, 2011, In vivo demonstration that α-synuclein oligomers are toxic, Proc. Natl. Acad. Sci. U.S.A., 108, 4194, 10.1073/pnas.1100976108 · DOI · Paper page
  17. Kahle, 2000, Physiology and pathophysiology of α-synuclein. Cell culture and transgenic animal models based on a Parkinson disease-associated protein, Ann. N.Y. Acad. Sci., 920, 33, 10.1111/j.1749-6632.2000.tb06902.x · DOI
  18. Giasson, 2002, Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein, Neuron, 34, 521, 10.1016/S0896-6273(02)00682-7 · DOI · Paper page
  19. Outeiro, 2003, Yeast cells provide insight into α-synuclein biology and pathobiology, Science, 302, 1772, 10.1126/science.1090439 · DOI
  20. Lakso, 2003, Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human α-synuclein, J. Neurochem., 86, 165, 10.1046/j.1471-4159.2003.01809.x · DOI
  21. Cooper, 2006, α-Synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson models, Science, 313, 324, 10.1126/science.1129462 · DOI
  22. Bennett, 1999, Degradation of α-synuclein by proteasome, J. Biol. Chem., 274, 33855, 10.1074/jbc.274.48.33855 · DOI · Paper page
  23. Tofaris, 2001, α-Synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome, FEBS Lett., 509, 22, 10.1016/S0014-5793(01)03115-5 · DOI · Paper page
  24. Ancolio, 2000, α-Synuclein and the Parkinson disease-related mutant A53T-α-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells, Neurosci. Lett., 285, 79, 10.1016/S0304-3940(00)01049-1 · DOI
  25. Lindersson, 2004, Proteasomal inhibition by α-synuclein filaments and oligomers, J. Biol. Chem., 279, 12924, 10.1074/jbc.M306390200 · DOI
  26. Anglade, 1997, Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging, Histol. Histopathol., 12, 603
  27. Sikorski, 1989, A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae, Genetics, 122, 19, 10.1093/genetics/122.1.19 · DOI
  28. Cheong, 2005, Atg17 regulates the magnitude of the autophagic response, Mol. Biol. Cell, 16, 3438, 10.1091/mbc.e04-10-0894 · DOI · Paper page
  29. Gietz, 1992, Improved method for high efficiency transformation of intact yeast cells, Nucleic Acids Res., 20, 1425, 10.1093/nar/20.6.1425 · DOI
  30. Sherman, 1991, Getting started with yeast, Methods Enzymol., 194, 3, 10.1016/0076-6879(91)94004-V · DOI
  31. Southern, 1975, Detection of specific sequences among DNA fragments separated by gel electrophoresis, J. Mol. Biol., 98, 503, 10.1016/S0022-2836(75)80083-0 · DOI
  32. Hoffman, 1987, A 10-min DNA preparation from yeast efficiently releases autonomous plasmids for transformation of Escherichia coli, Gene, 57, 267, 10.1016/0378-1119(87)90131-4 · DOI
  33. Abramoff, 2004, Image processing with Image J, Biophotonics Int., 11, 36
  34. Vida, 1995, A new vital stain for visualizing vacuolar membrane dynamics and endocytosis in yeast, J. Cell Biol., 128, 779, 10.1083/jcb.128.5.779 · DOI
  35. Lee, 1996, Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae, J. Biol. Chem., 271, 27280, 10.1074/jbc.271.44.27280 · DOI
  36. Takeshige, 1992, Autophagy in yeast demonstrated with proteinase-deficient mutants and conditions for its induction, J. Cell Biol., 119, 301, 10.1083/jcb.119.2.301 · DOI
  37. Dixon, 2005, α-Synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast, Genetics, 170, 47, 10.1534/genetics.104.035493 · DOI
  38. Lamphier, 1992, Multiple mechanisms mediate glucose repression of the yeast GAL1 gene, Proc. Natl. Acad. Sci. U.S.A., 89, 5922, 10.1073/pnas.89.13.5922 · DOI
  39. Lee, 1998, Proteasome inhibitors. Valuable new tools for cell biologists, Trends Cell Biol., 8, 397, 10.1016/S0962-8924(98)01346-4 · DOI · Paper page
  40. Ghislain, 1993, S. cerevisiae 26 S protease mutants arrest cell division in G2/metaphase, Nature, 366, 358, 10.1038/366358a0 · DOI
  41. Jones, 2002, Vacuolar proteases and proteolytic artifacts in Saccharomyces cerevisiae, Methods Enzymol., 351, 127, 10.1016/S0076-6879(02)51844-9 · DOI
  42. Dubiel, 1992, Subunit 4 of the 26 S protease is a member of a novel eukaryotic ATPase family, J. Biol. Chem., 267, 22699, 10.1016/S0021-9258(18)50002-8 · DOI
  43. Matsuura, 1997, Apg1p, a novel protein kinase required for the autophagic process in Saccharomyces cerevisiae, Gene, 192, 245, 10.1016/S0378-1119(97)00084-X · DOI
  44. Parr, 2007, The structure and function of Saccharomyces cerevisiae proteinase A, Yeast, 24, 467, 10.1002/yea.1485 · DOI
  45. Woolford, 1986, The PEP4 gene encodes an aspartyl protease implicated in the posttranslational regulation of Saccharomyces cerevisiae vacuolar hydrolases, Mol. Cell. Biol., 6, 2500
  46. Kamada, 2004, Autophagy in yeast. A TOR-mediated response to nutrient starvation, Curr. Top Microbiol. Immunol., 279, 73
  47. Wong, 1998, Antifungal activities of rapamycin and its derivatives, prolylrapamycin, 32-desmethylrapamycin, and 32-desmethoxyrapamycin, J. Antibiot., 51, 487, 10.7164/antibiotics.51.487 · DOI
  48. Karube, 2008, N-terminal region of α-synuclein is essential for the fatty acid-induced oligomerization of the molecules, FEBS Lett., 582, 3693, 10.1016/j.febslet.2008.10.001 · DOI
  49. Cookson, 2005, The biochemistry of Parkinson disease, Annu. Rev. Biochem., 74, 29, 10.1146/annurev.biochem.74.082803.133400 · DOI
  50. Murray, 2003, Role of α-synuclein carboxyl terminus on fibril formation in vitro, Biochemistry, 42, 8530, 10.1021/bi027363r · DOI
  51. Tsigelny, 2007, Dynamics of α-synuclein aggregation and inhibition of pore-like oligomer development by β-synuclein, FEBS J., 274, 1862, 10.1111/j.1742-4658.2007.05733.x · DOI
  52. Müller, 2000, Autophagic tubes. Vacuolar invaginations involved in lateral membrane sorting and inverse vesicle budding, J. Cell Biol., 151, 519, 10.1083/jcb.151.3.519 · DOI
  53. Outeiro, 2008, Formation of toxic oligomeric α-synuclein species in living cells, PLoS One, 3, e1867, 10.1371/journal.pone.0001867 · DOI
  54. Chen, 2005, α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease, Nat. Neurosci., 8, 657, 10.1038/nn1443 · DOI
  55. Volles, 2007, Relationships between the sequence of α-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity, J. Mol. Biol., 366, 1510, 10.1016/j.jmb.2006.12.044 · DOI
  56. Kim, 2006, A novel mechanism of interaction between α-synuclein and biological membranes, J. Mol. Biol., 360, 386, 10.1016/j.jmb.2006.05.004 · DOI
  57. Opazo, 2008, Accumulation and clearance of α-synuclein aggregates demonstrated by time-lapse imaging, J. Neurochem., 106, 529, 10.1111/j.1471-4159.2008.05407.x · DOI
  58. Fortun, 2003, Emerging role for autophagy in the removal of aggresomes in Schwann cells, J. Neurosci., 23, 10672, 10.1523/JNEUROSCI.23-33-10672.2003 · DOI
  59. Dyllick-Brenzinger, 2010, Reciprocal effects of α-synuclein overexpression and proteasome inhibition in neuronal cells and tissue, Neurotox Res., 17, 215, 10.1007/s12640-009-9094-1 · DOI
  60. Flower, 2007, YGR198w (YPP1) targets A30P α-synuclein to the vacuole for degradation, J. Cell Biol., 177, 1091, 10.1083/jcb.200610071 · DOI
  61. Paxinou, 2001, Induction of α-synuclein aggregation by intracellular nitrative insult, J. Neurosci., 21, 8053, 10.1523/JNEUROSCI.21-20-08053.2001 · DOI
  62. Chen, 2005, α-synuclein alters proteasome function, protein synthesis, and stationary phase viability, J. Biol. Chem., 280, 30009, 10.1074/jbc.M501308200 · DOI
  63. McNaught, 2001, Proteasomal function is impaired in substantia nigra in Parkinson disease, Neurosci. Lett., 297, 191, 10.1016/S0304-3940(00)01701-8 · DOI · Paper page
  64. Rideout, 2004, Involvement of macroautophagy in the dissolution of neuronal inclusions, Int. J. Biochem. Cell Biol., 36, 2551, 10.1016/j.biocel.2004.05.008 · DOI
  65. Olanow, 2006, Ubiquitin-proteasome system and Parkinson disease, Mov. Disord., 21, 1806, 10.1002/mds.21013 · DOI
  66. Tofaris, 2011, Ubiquitin ligase Nedd4 promotes α-synuclein degradation by the endosomal-lysosomal pathway, Proc. Natl. Acad. Sci. U.S.A., 108, 17004, 10.1073/pnas.1109356108 · DOI · Paper page
  67. Soper, 2011, Aggregation of α-synuclein in S. cerevisiae is associated with defects in endosomal trafficking and phospholipid biosynthesis, J. Mol. Neurosci., 43, 391, 10.1007/s12031-010-9455-5 · DOI
  68. Gitler, 2008, The Parkinson disease protein α-synuclein disrupts cellular Rab homeostasis, Proc. Natl. Acad. Sci. U.S.A., 105, 145, 10.1073/pnas.0710685105 · DOI
  69. Xilouri, 2009, Abberant α-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy, PLoS One, 4, e5515, 10.1371/journal.pone.0005515 · DOI

Cited by

Sorted by citations

See all 81

Metadata

Authors
Petroi, D., Popova, B., Taheri-Talesh, N., Irniger, S., Shahpasandzadeh, H., Zweckstetter, M., Outeiro, T. F., & Braus, G. H.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2012-08
Volume
287
Issue
33
Pages
27567-27579
ISSN
0021-9258
DOI
10.1074/jbc.m112.361865
Cited by
81
References
6
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review